NasdaqGS:AMGNBiotechs
Should Amgen’s (AMGN) IMDYLLTRA Win and Rare-Disease Data Shift Its High-Need Portfolio Strategy?
In early June 2026, Amgen reported that the European Commission granted marketing authorization for IMDYLLTRA (tarlatamab) in extensive-stage small cell lung cancer, while new Phase 3 and real-world data for UPLIZNA and TAVNEOS at EULAR 2026 supported their longer-term safety and disease-control profiles in rare autoimmune conditions.
Together, these updates underscore Amgen’s focus on high unmet-need niches, where differentiated mechanisms and maturing evidence can be especially influential...